0095: Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE

Thomas Winans¹, Nick Huang¹, Joshua Lewis¹, Xiaojing Wang¹, Tamas Faludi¹, Daniel Krakko², Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²North Carolina State University, Raleigh, NC, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY

Background/Purpose: The kynurenine (KYN) pathway has been linked to disease pathogenesis in patients with systemic lupus erythematosus (SLE) (https://pubmed.ncbi.nlm.nih.gov/26366134/). Genetically enforced overexpression of Rab4A activates the mechanistic target of rapamycin in SLE patients (https://pubmed.ncbi.nlm.nih.gov/31805010/. The present study was initiated to determine the pro-inflammatory mechanism of action of KYN in lupus-prone SLE1.2.3 triple congenic mice on the C57Bl/6 background (B6.TC) carrying constitutively active Rab4A^Q72L alleles (Rab4AKI) or lacking Rab4A in T cells (Rab4AKO).

Methods: KYN levels were measured within T cells and sera of mice carrying wild-type (WT), Rab4AKI and Rab4AKO alleles in female C57Bl/6 (B6) control mice and lupus-prone B6.TC mice using LC/MS. The effects of KYN on expression of its receptor CD98 and activation of mTOR complexes 1 (mTORC1, via pS6RP) and 2 (mTORC2, via pAkt) were studied by flow cytometry. Splenocytes were cultured in-vitro for 72 hours with or without KYN along with or without concurrent stimulation with lipopolysaccharide (LPS) or CD3/CD28. Mitochondrial mass and reactive oxygen species (ROS) were measured by flow cytometry using mitotracker Green (MTG) and hydroethidine (HE).

Results: KYN was accumulated in T cells and sera of B6.TC/Rab4A^Q72L female mice that exhibited increased expression of CD98 and activation mTORC1 and mTORC2 relative to B6.TC and B6.TC/Rab4A^KO controls. In C57Bl/6 splenocytes, KYN increased CD98 expression in CD4 and CD8 T cells (CD4 Unstim: FC=1.48, p=0.00012, CD8 Unstim: FC=1.68, p=2.1E-5, CD4 Stim: FC=1.36, p=0.00069, CD8 Stim: FC=1.51, p=0.00058) and significantly increased both mTORC1 (CD4 Unstim: FC=1.13, p=0.0169, CD4 Stim: FC=1.86, p=0.0086 CD8 Unstim: FC=1.24, p=0.0172, CD8 Stim: FC=1.49, p=0.0136) and mTORC2 (CD4 Unstim: FC=1.41, p=0.0003, CD4 Stim: FC=1.91, p=0.0018, CD8 Unstim: FC=1.42, p=0.0005, CD8 Stim: FC=1.55, p=0.0006). KYN increased mitochondrial mass (CD4 Stim: FC=1.25, p=0.0112, CD8 Stim: FC=1.87, p=0.0053) and ROS production (CD4 Stim: FC=2.2, p=0.0008, CD8 Stim: FC=2.34, p=0.0012) in both CD4 and CD8 T cells following KYN and CD3/CD28-stimulation.

KYN also expanded CD19+CD11c+ age-related B cells (ABCs) with or without LPS. KYN activated mTORC1 (CD19+: FC=1.15, p=0.012, ABCs: FC=1.97, p=0.0019) and mTORC2 (CD19+: FC=6.289, p=1.21E-5, ABCs: FC=3.70, p=0.00165) and CD98 expression (ABCs: FC=2.06, p=0.0144). Remarkably, the expression of CD138, a plasma cell marker, was also increased by concurrent LPS and KYN treatment (FC=2.76, p=0.001).

Conclusion: This study suggests that KYN accumulation in lupus-prone T cells causes a CD98-KYN-mTOR positive feedback loop which is enhanced by Rab4A activation, conferring secondary KYN-mediated expansion of ABCs and plasma cells. The Rab4A-CD98/mTOR/KYN positive feed-back loop may represent a mechanistic target for therapeutic intervention in SLE.







T. Winans: None; N. Huang: None; J. Lewis: None; X. Wang: None; T. Faludi: None; D. Krakko: None; L. Morel: None; A. Perl: None.